ARUD Zurich, Konradstr. 32, 8005 Zurich, Switzerland.
Drug Alcohol Depend. 2010 Jul 1;110(1-2):167-71. doi: 10.1016/j.drugalcdep.2010.02.016. Epub 2010 Mar 23.
Adherence to hepatitis C treatment is influenced by alcohol as is the action of interferon; yet the clinical significance of the latter remains unclear. The aim of our study was to investigate the influence of ongoing alcohol intake on sustained viral response (SVR) rates in adherent patients receiving hepatitis C treatment.
A retrospective analysis of patients treated with antiviral therapy for hepatitis C infection who were enrolled in the Swiss Hepatitis C Cohort Study was completed. Patients were eligible for the study if they had their HCV RNA tested 6 months following treatment completion and at least one cohort follow-up visit during HCV therapy, documenting the consumed amount of alcohol. They were assigned to three groups according to the amount of alcohol consumption: group A without alcohol consumption, group B < or =24 g/d alcohol and group C >24 g/d alcohol.
554 patients were included. Patients with at least 80% of the scheduled cumulative dose and duration did not significantly differ between the three groups. SVR rates according to alcohol consumption were 60% for non-drinkers (group A), 57% in group B and 50% in group C. No significant negative influence from alcohol consumption during therapy was observed in the multiple regression analysis for treatment success.
In this evaluation, we demonstrated comparable SVR rates in non-drinkers and in patients with daily amounts of alcohol intake up to 24 g during hepatitis C therapy.
酒精会影响到丙型肝炎的治疗依从性，干扰素也有类似作用；然而，后者的临床意义仍不清楚。我们的研究目的是调查在接受丙型肝炎治疗的依从性患者中，持续饮酒对持续病毒学应答（SVR）率的影响。
完成了对接受抗病毒治疗丙型肝炎感染的患者进行的瑞士丙型肝炎队列研究的回顾性分析。如果患者在治疗结束后 6 个月 HCV RNA 检测呈阳性，并且在 HCV 治疗期间至少有一次队列随访，记录饮酒量，则有资格参加研究。根据饮酒量将患者分为三组：A 组无饮酒，B 组饮酒量≤24 g/d，C 组饮酒量＞24 g/d。
共纳入 554 例患者。三组患者的治疗方案累积剂量和持续时间至少达到 80%的比例无显著差异。根据饮酒量，非饮酒者（A 组）的 SVR 率为 60%，B 组为 57%，C 组为 50%。在多因素回归分析中，治疗成功未观察到治疗期间饮酒的负面影响。
在这项评估中，我们发现非饮酒者和丙型肝炎治疗期间每日饮酒量达 24 g 以下的患者的 SVR 率相当。
